SCHEMBL23249944

SCHEMBL23249944

CN1C(=O)CCc2cc(Nc3cc(N4CCC(CO)CC4)c([N+](=O)[O-])cc3Cl)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL6 P41182 5/20 0.39
▸ BCOR Q6W2J9 5/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ MAPT P10636 4/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ TRIM24 O15164 2/20 0.37
▸ SYK P43405 1/20 0.36
▸ CYP11B1 P15538 2/20 0.36
▸ CYP11B2 P19099 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ IDH1 O75874 1/20 0.35
▸ INSR P06213 2/20 0.35
▸ ALK Q9UM73 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29874089 1.00 BCL6 (0.39) BCL6BCORKMT2AGABRG2GABRB3
SCHEMBL23267269 0.87 BCL6 (0.37) BCL6BCORKMT2AGABRG2GABRB3
SCHEMBL29874016 0.87 BCL6 (0.40) BCL6BCORKMT2AGABRG2GABRB3
SCHEMBL23249920 0.87 BCL6 (0.40) BCL6BCORKMT2AGABRG2GABRB3
SCHEMBL31595469 0.77 CRBN (0.50) ALK
SCHEMBL23249934 0.74 CRBN (0.38) BCL6BCOR
SCHEMBL23249931 0.74 CRBN (0.38) BCL6BCOR
SCHEMBL31099152 0.73 ALDH1A1 (0.55) KMT2AMAPTMEN1ALDH1A1MAPK1
SCHEMBL23249961 0.73 ALDH1A1 (0.55) KMT2AMAPTMEN1ALDH1A1MAPK1
SCHEMBL31595459 0.72 MAPT (0.41) BCL6BCORMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12310975-B2 Modulators of BCL6 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2025-05-27 — — US disclosed
CN-115397821-A Bifunctional molecules containing an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety 阿尔维纳斯运营股份有限公司 2022-11-25 — — CN disclosed
US-20220323457-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-10-13 — — US disclosed
WO-2021077010-A1 BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY ARVINAS OPERATIONS, INC. (US) 2021-04-22 — — WO disclosed
WO-2021077010-A1 BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY ARVINAS OPERATIONS, INC. (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12310975-B2 Modulators of BCL6 proteolysis and associated methods of use BCL6, BCL6B, BCL3 BCL6 1/4885BCOR 4/4885KMT2A 679/4885
US-20220323457-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 BCL6 1/4885BCOR 4/4885KMT2A 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback